TRITON2: An international, multicentre, open-label phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Meeting Abstract

  

Authors:	Heidenreich, A.; Carl, S.; Feyerabend, S.; Gleissner, J.; Grullich, C.; Heinrich, B.; Merseburger, A.; Miller, K.; Stenzl, A.; Steuber, T.; Wirth, M.; Watkins, S.; Simmons, A.; Go, J.; Golsorkhi, T.; Abida, W.; Scher, H. I.
Abstract Title:	TRITON2: An international, multicentre, open-label phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Meeting Title:	33rd Deutscher Krebskongress
Journal Title:	Oncology Research and Treatment
Volume:	41
Issue:	Suppl. 1
Meeting Dates:	2018 Feb 21-24
Meeting Location:	Berlin, Germany
ISSN:	2296-5270
Publisher:	S. Karger AG
Date Published:	2018-02-01
Start Page:	75
Language:	English
ACCESSION:	WOS:000424914300199
PROVIDER:	wos
PUBMED:	29421791
DOI:	10.1159/000487109
Notes:	"German Cancer Congress" -- Meeting Abstract: 542 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/122715